Kestra Medical Technologies, Ltd. announced the pricing of its underwritten public offering of 6,000,000 common shares at $23.00 per share, with expected gross proceeds of $138,000,000. The underwriters have a 30-day option to purchase up to an additional 900,000 shares. The offering is set to close on December 4, 2025. BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC, and Wells Fargo Securities are acting as bookrunners for the offering. Interested investors can access the preliminary prospectus on the SEC’s website.

The registration statement for the securities was declared effective on December 2, 2025. This press release does not constitute an offer to sell securities. Forward-looking statements in this release involve risks and uncertainties, and actual results may differ. Kestra Medical Technologies, Ltd. focuses on transforming patient outcomes in cardiovascular disease with wearable medical devices and digital healthcare technologies.

Read more at GlobeNewswire: Kestra Medical Technologies, Ltd. Announces Pricing of